Wu Ruicheng, Li Dengxiong, Zhang Shuxia, Wang Jie, Chen Kai, Tuo Zhouting, Miyamoto Akira, Yoo Koo Han, Wei Wuran, Zhang Chi, Feng Dechao, Han Ping
Department of Urology, Institute of Urology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Research Core Facilities, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
J Cancer Res Clin Oncol. 2024 Mar 12;150(3):123. doi: 10.1007/s00432-024-05640-6.
There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment.
Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method.
TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells.
TGM1 has the potential to serve as both a prognostic marker and a drug target.
目前关于1型转谷氨酰胺酶（TGM1）在肿瘤中的研究数量有限。本研究的目的是对各种类型的癌症进行全面分析，以确定TGM1在肿瘤中的预后意义，并研究其在免疫环境中的作用。
从TCGA数据库中检索泛癌和突变数据，并使用R（版本3.6.4）及其相关软件包进行分析。检测了TGM1的表达差异和预后，以及它与肿瘤异质性、干性、突变图谱和RNA修饰的相关性。此外，使用TIMER方法研究了TGM1表达与肿瘤免疫之间的关系。
TGM1在各种肿瘤和正常样本中的表达不同，并且与肾透明细胞癌（KIRC）、腺样囊性癌（ACC）、皮肤黑色素瘤（SKCM）、肝癌（LIHC）和睾丸胚胎性癌（STES）的总生存期和无进展生存期相关。在肝癌中，我们发现TGM1表达与6个肿瘤干性指标呈负相关。膀胱癌（BLCA）、肝癌和肾透明细胞癌的突变频率分别为1.7%、0.3%和0.3%。在膀胱癌和乳腺癌（BRCA）中，TGM1表达与CD4 + T细胞、CD8 + T细胞、中性粒细胞和树突状细胞的浸润之间存在显著相关性。
TGM1有潜力作为一种预后标志物和药物靶点。
